These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30805895)

  • 1. Romosozumab: First Global Approval.
    Markham A
    Drugs; 2019 Mar; 79(4):471-476. PubMed ID: 30805895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romosozumab: A Review in Postmenopausal Osteoporosis.
    Paik J; Scott LJ
    Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
    Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
    N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    Cosman F; Crittenden DB; Adachi JD; Binkley N; Czerwinski E; Ferrari S; Hofbauer LC; Lau E; Lewiecki EM; Miyauchi A; Zerbini CA; Milmont CE; Chen L; Maddox J; Meisner PD; Libanati C; Grauer A
    N Engl J Med; 2016 Oct; 375(16):1532-1543. PubMed ID: 27641143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romosozumab: a novel bone anabolic treatment option for osteoporosis?
    Kerschan-Schindl K
    Wien Med Wochenschr; 2020 Apr; 170(5-6):124-131. PubMed ID: 31858345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: An observational study.
    Mineta K; Nishisho T; Okada M; Kamada M; Sairyo K
    Bone; 2024 Sep; 186():117164. PubMed ID: 38871265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical approach for anabolic treatment of bone fragility with romosozumab.
    Cianferotti L; Cipriani C; Palermo A; Viapiana O; Zavatta G; Mazziotti G
    J Endocrinol Invest; 2024 Nov; 47(11):2649-2662. PubMed ID: 38789679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sequential treatment of osteoporosis with anti-sclerostin.].
    Inoue D
    Clin Calcium; 2019; 29(3):363-369. PubMed ID: 30814383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amgen and UCB announce increased cardiovascular risk in patients receiving romosozumab, an anti-sclerotin antibody.
    Rheumatology (Oxford); 2017 Aug; 56(8):e21. PubMed ID: 28854619
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular Safety and Sclerostin Inhibition.
    Langdahl BL; Hofbauer LC; Forfar JC
    J Clin Endocrinol Metab; 2021 Jun; 106(7):1845-1853. PubMed ID: 33755157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
    Turk JR; Deaton AM; Yin J; Stolina M; Felx M; Boyd G; Bienvenu JG; Varela A; Guillot M; Holdsworth G; Wolfreys A; Dwyer D; Kumar SV; de Koning EM; Qu Y; Engwall M; Locher K; Ward LD; Glaus C; He YD; Boyce RW
    Regul Toxicol Pharmacol; 2020 Aug; 115():104697. PubMed ID: 32590049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis.
    Prather C; Adams E; Zentgraf W
    Am J Health Syst Pharm; 2020 Nov; 77(23):1949-1956. PubMed ID: 32880646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
    N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials.
    Kobayashi T; Hara M; Shimanoe C; Morimoto T; Masaaki M; Ito K; Shimazaki T
    J Bone Miner Metab; 2024 Sep; 42(5):492-502. PubMed ID: 38977437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis drug licensed for women with high fracture risk.
    Traynor K
    Am J Health Syst Pharm; 2010 Jul; 67(13):1046. PubMed ID: 20554585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.